Maui Derm

The limited armamentarium of systemic therapies for atopic dermatitis has already been expanded with the approval of dupilumab. Forthcoming systemic therapies are expected to include a new biologic and three new Janus kinase (JAK) inhibitors.

Update tracks trending factors changing the treatment landscape.

Trichometric analysis helps evaluate whether treatment is working for patients experiencing hair loss and what adjustments need to be made to the regimen.

This is the first overhaul in a quarter century that simplifies evaluation and management and increases flexibility.

Pre- and postmarketing psoriasis studies support novel drug results and new labeling.

New treatments for atopic dermatitis offer more options with favorable safety and efficacy.

According to one expert, recently completed phase 3 trials of novel drugs have shown impressive results, with 2021 expected to be an exciting year that will bring further advances in treatment options for patients with moderate-to-severe plaque psoriasis.

Top educators in dermatology will come together to deliver CME lectures and engaging panel discussions via a premiere virtual platform. Learn more about MauiDerm Connect coming September 23-27.

Speaking about device-based acne treatments at Maui Derm for Dermatologists 2020 meeting, Fernanda Sakamoto, Ph.D., M.D., discussed PDT and other approaches for targeting the sebaceous gland.

George Martin, M.D., dermatologist and program director for the Maui Derm meetings, has been working with the Maui Derm faculty, immunologists and members of industry to share emerging data regarding the novel coronavirus with the dermatology community. Listen to his insights in this video.

In a skit depicting Carnac the Magnificent, Drs. Rosen and Bhatia presented on 2020's new drugs and technologies at the current Maui Derm for Dermatologists, all with a magical twist.

In his presentation at the current Maui Derm 2020, Dr. Curtis Cole tackled the controversy of how SPF labeling can differ significantly from the actual protection.

Medical device company, Soliton will present results from their 12-week study looking at the treatment of fibrotic scars using their RAP device at Maui Derm Jan. 25-29.

George Martin, M.D., presented diagnostic and treatment tips on actinic keratosis, basal cell carcinoma and squamous cell carcinoma at the Maui Derm NP + PA summer 2019 meeting.

Kevin S. Pinski, M.D., shared what providers need to know and do to prevent and manage injectable complications at the Maui Derm NP + PA summer 2019 meeting.

Suneel Chilukuri, M.D. presented on the science of neuromodulators at the October Maui Derm NP + PA Fall 2019 meeting in Asheville, N.C. Read insights gleaned from his presentation in this article.

The 12th Annual Maui Derm for Dermatologists provides access to industry leaders and a faculty of highly respected dermatologists who offer intimate group discussions and presentations devoted to key topics in medical and aesthetic dermatology.

Highlights, updates, and all other coverage right from Maui Derm 2015

Dermatologists at the Maui Derm 2015 meeting learned that they should be on the lookout for patients with acne, especially women. And, they should be cautious about antibiotic use in young patients.

Itchy patients with no rash and no apparent cause may be the bane of the dermatology world, but one expert told colleagues at the Maui Derm 2015 meeting to remember the end game: patient relief.

Psoriasis goes beyond a skin disease, dermatologists learned at the Maui Derm 2015 meeting this week. Physicians are becoming increasingly aware that severe cases of psoriasis are indications of dangerous systemic inflammation.

Dermatologists should keep an eye out for acne in pre-adolescent children as young as one year because pimples may be a sign of serious medical problems, a leading dermatologist told a crowd at the Maui Derm 2015 conference this week.

Highlights of dermatology news in 2014 include promising data about nivolumab (Opdivo, Bristol-Myers Squibb) for melanoma and a new class of drugs that may help patients with stubborn cases of alopecia areata, a top dermatologist told attendees at the Maui Derm 2015 meeting Monday.

Promising new treatments for rosacea and leishmaniasis are among the highlights of a Maui Derm conference session about new drugs in dermatology.

The hot topics of discussion at Maui Derm 2012 were January’s Food and Drug Administration approval of two innovative products in the cutaneous oncology arena: Picato (ingenol mebutate, LEO Pharma) 0.015 percent gel and 0.05 percent gel for the treatment of actinic keratoses (AKs) and Erivedge (vismodegib, Genentech) for the treatment of advanced basal cell carcinoma. At MauiDerm I discussed the data on Picato and Keith Flaherty, M.D., an oncologist from Massachusetts General Hospital, discussed Erivedge.